This 2013 review discusses pharmacologic options for obesity management, emphasizing the role of medications as adjuncts to lifestyle modifications. At the time, four FDA-approved drugs were available: orlistat, lorcaserin (Belviq), phentermine/topiramate (Qsymia), and naltrexone/bupropion (Contrave). Orlistat functions by inhibiting fat absorption, while the others act centrally to suppress appetite. Clinical
